MedPath

Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C

Completed
Conditions
Hepatitis C, Chronic
Registration Number
NCT00216775
Lead Sponsor
Kyoto University
Brief Summary

The purpose of this study is to evaluate the efficacy and safety of low-dose interferon-alfa-2b plus ribavirin compared to the standard-dose of the same combination in patients with chronic hepatitis C.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Clinical diagnosis of Chronic Hepatitis C. Must be infected with genotype 1b viruses
Exclusion Criteria
  • Hemoglobin levels<8.5g/dL,
  • Platelet counts<50,000/mm3,
  • Total polymorphonuclear counts<1000/mm3
  • Pregnancy,
  • Renal dysfunction,

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
rate of sustained viral response6 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

Department of Gastroenterology and Hepatology, Kyoto University Hospital

🇯🇵

Kyoto, Japan

Kitano Hospital

🇯🇵

Osaka, Japan

Osaka Red Cross Hospital

🇯🇵

Osaka, Japan

Wakayama Red Cross Hospital

🇯🇵

Wakayama, Japan

Department of Gastroenterology and Hepatology, Kyoto University Hospital
🇯🇵Kyoto, Japan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.